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STUDY PROTOCOL Open Access
The efficacy of vigorous-intensity exercise as an
aid to smoking cessation in adults with elevated
anxiety sensitivity: study protocol for a
randomized controlled trial
Jasper A J Smits1*, Michael J Zvolensky2, David Rosenfield1, Bess H Marcus3, Timothy S Church4,
Georita M Frierson5, Mark B Powers1, Michael W Otto6, Michelle L Davis1, Lindsey B DeBoer1 and Nicole F Briceno1
Abstract
Background: Although cigarette smoking is a leading cause of death and disability in the United States (US), over
40 million adults in the US currently smoke. Quitting smoking is particularly difficult for smokers with certain types
of psychological vulnerability. Researchers have frequently called attention to the relation between smoking and
anxiety-related states and disorders, and evidence suggests that panic and related anxiety vulnerability factors,
specifically anxiety sensitivity (AS or fear of somatic arousal), negatively impact cessation. Accordingly, there is merit
to targeting AS among smokers to improve cessation outcome. Aerobic exercise has emerged as a promising aid
for smoking cessation for this high-risk (for relapse) group because exercise can effectively reduce AS and other
factors predicting smoking relapse (for example, withdrawal, depressed mood, anxiety), and it has shown initial
efficacy for smoking cessation. The current manuscript presents the rationale, study design and procedures,
and design considerations of the Smoking Termination Enhancement Project (STEP).
Methods: STEP is a randomized clinical trial that compares a vigorous-intensity exercise intervention to a health
and wellness education intervention as an aid for smoking cessation in adults with elevated AS. One hundred
and fifty eligible participants will receive standard treatment (ST) for smoking cessation that includes cognitive
behavioral therapy (CBT) and nicotine replacement therapy (NRT). In addition, participants will be randomly
assigned to either an exercise intervention (ST+EX) or a health and wellness education intervention (ST+CTRL).
Participants in both arms will meet 3 times a week for 15 weeks, receiving CBT once a week for the first 7 weeks,
and 3 supervised exercise or health and wellness education sessions (depending on randomization) per week for
the full 15-week intervention. Participants will be asked to set a quit date for 6 weeks after the baseline visit, and
smoking cessation outcomes as well as putative mediator variables will be measured up to 6 months following the
quit date.
(Continued on next page)
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Discussion: The primary objective of STEP is to evaluate whether vigorous-intensity exercise can aid smoking
cessation in anxiety vulnerable adults. If effective, the use of vigorous-intensity exercise as a component of smoking
cessation interventions would have a significant public health impact. Specifically, in addition to improving smoking
cessation treatment outcome, exercise is expected to offer benefits to overall health, which may be particularly
important for smokers. The study is also designed to test putative mediators of the intervention effects and
therefore has the potential to advance the understanding of exercise-anxiety-smoking relations and guide future
research on this topic.
Clinical trials registry: ClinicalTrials.gov, NCT01065506, http://clinicaltrials.gov/ct2/show/NCT01065506
Keywords: Smoking, Smoking cessation, Intervention, Randomized controlled trial, Exercise, Aerobic exercise,
Anxiety, Anxiety sensitivity
Background
Tobacco use: scope of problem
Cigarette smoking is a leading cause of death in the United
States (US), contributing to over 440,000 deaths each year
[1]. Cigarette smoking is implicated in various types of
medical illness, including heart disease, pulmonary diseases,
and cancer [2]. Importantly, quitting smoking decreases the
risk of developing medical problems and may increase sur-
vival time among those persons who have already devel-
oped medical problems [3]. However, despite a substantial
decline in smoking prevalence since the 1960s, smoking
remains prevalent, with a recent report estimating that
20.8% of US adults are current cigarette smokers [4].
Reports further indicate that although most smokers (70%)
are motivated to quit [5], cessation failure (that is, relapse)
is high among smokers who try to quit smoking on their
own (90% to 95% [6]) or attend treatment programs (60%
to 80% [7,8]). In fact, since the mid 1970s, abstinence rates
associated with standard behavioral pharmacological
therapies have decreased [9].
One response to these observations has been a call for
the development of specialized or targeted interventions
that address specific needs of smokers who are at higher
risk for relapse [10,11]. Guiding this direction is the selec-
tion/hardening hypothesis of smoking prevalence, which
posits that smokers who are unable to quit successfully
are ‘burdened’ by factors that pose particular challenges to
quitting [12-14]. According to this perspective, continuing
smokers are mostly at-risk smokers who cannot quit, thus
explaining why smoking prevalence has begun to stabilize
over the years.
Smoking and anxiety and its disorders
Anxiety psychopathology co-occurs with smoking at
rates that exceed those found in non-psychiatric popula-
tions [15]. Reported rates of smoking are highest among
individuals with panic-related problems and other anx-
iety disorders where panic attacks are particularly com-
mon (for example, social anxiety disorder, posttraumatic
stress disorder [PTSD], generalized anxiety disorder
[16-20]). Moreover, the observed association between
smoking and anxiety psychopathology is not due to
sociodemographic characteristics, other psychiatric co-
morbidities, or symptom overlap in diagnostic criteria for
anxiety disorders and nicotine dependence [21]. Numer-
ous studies indicate anxiety disorders significantly impair
cessation success [16,22,23]. For example, Piper and col-
leagues [24] examined the relation of psychiatric disor-
ders to tobacco dependence and cessation outcomes
among 1,504 people making a pharmacologically-aided
smoking cessation attempt as part of a clinical trial. Six
months after quitting, those with an anxiety disorder had
the lowest abstinence rates.
Anxiety sensitivity and smoking
In order to isolate possible therapeutic targets and trans-
diagnostic mechanisms for treatment development, we
and others have explored numerous factors that could
account for why anxiety is often associated with smoking
relapse (for example, severity of nicotine dependence,
age of smoking onset, broad-based tendency to experi-
ence negative mood). Here, some of the strongest and
most consistent evidence has been evident for anxiety
sensitivity (AS) [25]. AS is defined as the fear of anxiety
or related sensations (for example, racing heart, chest
pain, rapid breathing, dizziness). This fear is often fueled
by concerns about physical (for example, heart attack,
stroke, death), social (for example, embarrassment), or
mental (for example, going crazy, losing control) cata-
strophes. Historically, AS has been studied to better
understand the etiology and maintenance of anxiety and
its disorders, particularly panic disorder and PTSD
[26-33]. More recent work suggests that AS also plays a
formative role in smoking behavior. For example, AS is
positively correlated with smoking to reduce negative affect,
but often not with other smoking motives (for example,
handling, taste [34-39]). Other studies have found that AS
is related to negative affect reduction expectancies for
smoking (beliefs that smoking will reduce negative affect
[40,41]). Additionally, smokers high in AS perceive the
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prospect of quitting as both a more difficult and person-
ally threatening experience [42], possibly due to a hyper-
sensitivity to aversive internal sensations such as nicotine
withdrawal symptoms [43] or elevated state anxiety
[44-46]. High AS smokers compared to those low in AS
also experience greater increases in positive affect from
pre- to post-cigarette consumption and report greater
smoking satisfaction [47]. Perhaps most notably, AS is
significantly associated with less success during smoking
cessation attempts [48]. Specifically, higher levels of AS
are related to greater odds of early lapse [40] and relapse
during quit attempts [49-51]; these effects are not
explained by smoking rate or nicotine dependence, nico-
tine withdrawal symptoms, or trait-like negative mood
propensity [50].
Collectively, these studies suggest that AS is associated
with problems during cessation and is correlated with
smoking to reduce negative affect. Moreover, AS moder-
ates the risk of smoking in terms of the development of
panic attacks, suggesting that regular smokers with
higher AS are at increased risk for experiencing panic-
related problems [52]. Unlike many other panic risk
factors (for example, family history of psychiatric ill-
ness), AS is malleable in response to exposure-based
intervention and can therefore be specifically targeted
for therapeutic change. As we now discuss, exercise is
one method for reducing AS and thereby promoting
abstinence for this high-risk group.
Exercise as an intervention for reducing AS and
promoting smoking abstinence
There are several findings that support studying the effi-
cacy of exercise as an aid to smoking cessation
among smokers with elevated AS. First, exercise has
been shown to significantly reduce AS [53,54], per-
haps through repeated exposure to feared bodily sen-
sations (for example, sweating, rapid heartbeat [55]).
Second, exercise has been shown to reduce nicotine
withdrawal symptoms [56,57], negative affect [56],
and depressed mood and anxiety [55,58,59], all of
which predict cessation relapse, particularly among
persons with elevated AS [50]. Third, there is evi-
dence [60] of the efficacy of exercise as an effective
smoking cessation intervention when it is supervised
and uses an intense dose (for example, vigorous-in-
tensity, three times per week over 12 weeks). This
particular trial [60] involved the randomization of sed-
entary female smokers to either a 12-week cognitive-behav-
ioral smoking cessation program with vigorous-intensity
exercise (three sessions a week of 30 to 40 min at 60% to
85% of heart rate reserve), or a 12-week cognitive-behav-
ioral smoking cessation program with contact control
(three 45 to 60 min health education sessions a week). All
participants initiated the intervention 3 weeks prior to the
quit date of the smoking cessation program. The results
revealed that participants assigned to the exercise condition
were more likely than participants assigned to the control
intervention to be continuously abstinent during the 8
weeks (19.4% vs. 10.2%), 20 weeks (16.4% vs. 8.2%), and 60
weeks (11.9% vs. 5.4%) following the quit day.
Although existing work on exercise and smoking
cessation is indeed promising (see [57] for a review), it
cannot speak to the utility of exercise as an aid for
smoking cessation among individuals with elevated AS.
Indeed, previous exercise-smoking cessation studies
have tended to exclude for psychiatric vulnerability or
disorders [57]. These exclusion criteria may preclude
generalizing the studies’ findings to at risk populations
such as high AS smokers, a population who may arguably
benefit most from such interventions. Second, exercise
studies conducted to date did not advance the knowledge
of the mechanisms by which exercise facilitates the effi-
cacy of standard smoking cessation protocols. Thus,
there are no data on the potential mediating effects of
reductions in AS, nicotine withdrawal symptoms,
depressed mood, and anxiety on reductions in smoking.
Third, many exercise studies conducted to date have fo-
cused exclusively on women [57]. Accordingly, there is
little empirical information about the utility of exercise
for smoking cessation for men. Although exercise effects
are likely to benefit men and women [54], marshalling
empirical data across sex is an important task for
exercise-smoking oriented work.
Study aims
The primary aim of STEP is to compare the relative
effects of two smoking cessations interventions (stand-
ard treatment combined with exercise (ST+EX) vs.
standard treatment combined with a wellness education
intervention (ST+CTRL)) on three central smoking ces-
sation outcomes: (1) point prevalence abstinence (PPA);
(2) time to first smoking lapse; and (3) time to first
smoking relapse. Smoking will be measured by self-
report using the time-line follow back (TLFB) procedure
and verified by carbon monoxide and cotinine assess-
ment (see Assessments below). We hypothesize that
PPA will be higher, both in the short term and long
term, for those in the ST+EX condition than for those in
the ST+CTRL condition. Similarly, we expect the rate of
decline in abstinence over time to be shallower (smaller)
in ST+EX than in ST+CTRL. Lastly, we expect mean
time to first lapse and to relapse to be greater for those
in the ST+EX compared to those in the ST+CTRL
condition.
The secondary aim of STEP is to investigate the putative
mechanisms by which exercise increases smoking cessa-
tion outcomes. Figure 1 illustrates the central predictions
of our model of the mechanisms of change in abstinence.
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We expect that: (1) treatments over time will directly
cause changes in abstinence and in all proposed mediators
of change in abstinence (as indicated by the ‘a’ paths in
Figure 1 linking time to withdrawal symptoms, AS, anx-
iety symptoms, depressed mood, and abstinence); (2)
the effect of treatment over time on all of these vari-
ables will be moderated by treatment condition, such
that those receiving ST+EX will improve more than
those receiving ST+CTRL; (3) changes in each mediator
over time will lead to improvements in abstinence rates
over time (as indicated by the ‘b’ paths in Figure 1);
and Table 1 decreases in AS over time will lead to
improvements in anxiety symptoms and depressed
mood over time (‘d’ paths in Figure 1).
The present manuscript details the STEP protocol. In
addition to providing a detailed description of a novel
exercise intervention for high AS smokers, this manu-
script also provides a rationale for design considerations
of the study. Specifically, these include the development
of an exercise intervention of appropriate length and in-
tensity, the determination of a comparable control
group, the decision to use the nicotine patch, and the
selection of meaningful follow-up time points.
Methods/Design
Overview
One hundred and fifty eligible participants who reported
elevated AS and who are currently smoking will receive
the standard treatment (ST) for smoking cessation:
cognitive behavioral therapy (CBT) for relapse preven-
tion along with nicotine replacement therapy (NRT).
In addition, all participants will be randomized to
participate in either an exercise intervention (ST + EX)
or a health and wellness education support group (ST +
CTRL). As can be seen in Figure 2, all participants will
meet three times a week for 15 weeks, receiving CBT
once a week for the first 7 weeks, and three exercise or
wellness sessions (depending on randomization) per
week for the entire 15-week intervention. The partici-
pants will be asked to set a quit date for 6 weeks after the
baseline visit and smoking cessation outcomes will be
measured up to 6 months following the quit date (see
Figure 2).
The Institutional Review Board of Southern Methodist
University approved the study and a Data Safety and
Monitoring Board provides ongoing monitoring. The
study is funded by the National Institute of Drug Abuse
(NIDA; R01DA027533) and is registered on clinicaltrials.
gov (ID: NCT01065506). The STEP study is currently in
the recruitment phase.
Eligibility criteria
Participants will be sedentary men and women with high
AS, ages 18 to 65, who have been daily smokers for at
least 1 year and are currently smoking an average of at
least 10 cigarettes per day. High AS is defined by a score
of 20 or greater on the 16-item Anxiety Sensitivity Inven-
tory (that is, above the community norm and a cut-off
point shown to be associated with increased risk of fu-
ture panic and other anxiety problems; [61]). Sedentary is
defined as participating in moderate-intensity exercise
less than 2 days/week (duration must be 30 min or less
each time). Participants must also report a motivation to
quit smoking in the next month of at least 5 on a 10-
point scale. In addition, results of a physical exam and
maximal exercise test conducted by a protocol-approved
physician (described in further detail under Assessments)
must indicate that no conditions are present that would
Figure 1 Model of study aims and hypotheses.
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otherwise be a contraindication of exercise. Participants
must also be capable and willing to provide informed
consent, attend all study sessions, and adhere to study
protocol.
To preserve high internal validity and reduce risk of
adverse events, we employ the following exclusion cri-
teria: (1) use of other tobacco products; (2) general
medical condition(s) that contraindicate exercise; (3)
resting blood pressure of ≥160 systolic and/or 100
diastolic who are not receiving treatment for high
blood pressure; (4) blood lipid levels ≥240 mg/dl with
LDL-C ≥160 mg/dl or triglyceride levels ≥300 mg/dl
(individuals receiving medical treatment for lipid ab-
normalities with lipid levels above the cut-offs will be
eligible with physician written approval); (5) body
mass index ≥40; (6) currently suicidal or high suicide
risk; (7) current or past psychotic disorders of any
type, or co-morbid psychiatric conditions that are
relative or absolute contraindications to the use of
any treatment option in the study protocol; (8) cur-
rently pregnant, planning on becoming pregnant in
the next year, or current breastfeeding; (9) abuse or
dependence of alcohol, depressants, dissociative anes-
thetics, hallucinogens, opioids, or cocaine or cannabis
dependence within the last 6 months; (10) psychotherapy
initiated within the past 3 months, or ongoing psycho-
therapy of any duration directed specifically toward the
treatment of anxiety or mood disorder other than general
supportive therapy; and (11) current use of any psycho-
therapy or pharmacotherapy for smoking cessation not
provided by the researchers, including Chantix, Zyban,
Welbutrin, and Nortriptyline.
Table 1 Overview of assessments
Protocol weeks
>−3 −2 −1 0 1-5 6 8 10 14-30
End points
Prescreen Screen
Visit 1
Screen
Visit 2
Baseline
WK −6
WK −5 to
WK −1
WK 0
Quit Week
WK 2
Follow-up
WK 4
Follow-up
WK 8, 10, 16, 24
Follow-up
Measures for screening
Smoking history X
Motivation to quit X
ASI-16 X
Exercise frequency X
C-SSRS X
SCID-NP X
Drug screen X
Medical history X
Physical exam X
Laboratory testing X
Maximal exercise testing X X
Measures of post-cessation smoking outcomes
Point prevalence abstinence X X X X X X
Timeline follow-back X X X X X
Carbon monoxide X X X X X X X
Saliva cotinine X
Measures of putative mediators
MWS X X X X X X
ASI-III X X X X X X
IDAS X X X X X X
Measures of treatment integrity/acceptance
Credibility/Expectancy X
Therapist adherence X X X X X
Patient adherence X X X X X
Fitness X X
Adverse events X X X X X
Concurrent treatment X X X X X X X
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Screening and randomization
Prescreen
An Internet prescreen is conducted to determine potential
eligibility for all potential participants who respond or are
referred to us via various recruitment strategies. The pre-
screen is the first point of contact for participants, and it
allows us to ask critical information about the potential
participant’s willingness and ability to commit to the fre-
quency of clinic visits as well as the assessment of inclu-
sion criteria. The Internet site used to obtain participant
information (including both the prescreening and subse-
quent assessment batteries) is a safe and secure website
called Qualtrics. Qualtrics is a sophisticated web survey
tool that has been used in experimental research and is
designed to ensure the security of data transmission and
protection. Qualtrics offers Transport Layer Security
(TLS) encryption (HTTPS) and survey security options
like password protection and HTTP referrer checking.
Qualtrics is a HIPAA compliant company, and servers are
stored in a tier one data storage facility that includes ad-
equate security measures.
Persons who appear eligible based on the online pre-
screen receive a follow-up telephone call to verify prescreen
eligibility. Those deemed eligible are invited to come to the
study facility for diagnostic and medical screening.
Screening visit 1: Psychiatric diagnostic screening
Upon arrival, participants receive an informed consent
form explaining the details of the study, potential
benefits and risks of participation, and the procedures
they will undergo if they choose to participate. After
reading the informed consent, a study coordinator dis-
cusses these issues with the potential participant and
answers any questions he or she has about the study and
participation. If the individual chooses to sign the
informed consent, he or she begins the psychiatric
evaluation.
The psychiatric evaluation begins with the Structured
Clinical Interview for DSM-IV Diagnosis of Axis I
Disorders Non-Patient Version (SCID-NP) to evaluate
the presence psychiatric exclusion criteria. The interview
also assesses for primary and secondary diagnoses (if
applicable). Participants complete a cheek swab drug
test to verify their previously self-reported lack of sub-
stance use. Once the initial screening visit is complete,
participants are referred to an outside clinic for medical
screening and maximal exercise testing.
Screening visit 2: Medical screening and maximal exercise
testing
The medical examination is used to evaluate potential
participants’ eligibility to begin a program of physical
activity by determining risk based on exercise guide-
lines established by the American College of Sports
Medicine (ACSM). The examining physician conducts
a physical examination that consists of reviewing the
participants’ past medical and health history, and their
current physical health. Subsequently, the physician
Figure 2 Overview of study flow.
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orders laboratory testing and complete exercise testing
on a treadmill (see below). Based on the information
collected during this visit (for example, medical his-
tory, physical exam, laboratory testing, exercise test-
ing), the examining physician determines whether the
participant meets medical eligibility criteria for the
study. Additionally, the data obtained during exercise
testing is used to determine (1) the prescribed exercise
intensity for participants randomized to the ST+EX
condition and (2) pretreatment fitness (functional cap-
acity) as indexed by metabolic equivalents (METs).
Baseline/randomization
If deemed eligible after the diagnostic and medical screen-
ing visits (based on the inclusion and exclusion criteria
presented previously), participants are invited to come in
for baseline assessments within 3 weeks. We selected a
3-week window to allow sufficient time to form a cohort/
group while also minimizing pre-randomization attrition.
Baseline assessments for both conditions include vital
signs, height and weight, and a reading of expired air car-
bon monoxide levels (assessed with a carbon monoxide
monitor [62]). Additionally, participants meet their group
members, receive an introduction to the study, and are
informed of their condition assignment, which takes place
after the first group member arrives for the baseline session.
The project Biostatistician (DR) oversees the randomization
process. Participants are randomized to either the ST
+CTRL or ST+EX conditions. Prior to analyzing the data,
the project Biostatistician will check the balance of
randomization and statistically control for any factors that
are imbalanced.
STEP interventions
Standard treatment for smoking cessation (ST)
All participants receive standard treatment for smoking
cessation based on the most recent clinical practice
guideline from the US Department of Health and
Human Services, Treating Tobacco Use and Dependence
[2]. This includes CBT for smoking cessation combined
with NRT. This standard treatment is delivered through
manualized once-weekly 60-min sessions over a 7-week
period (Smoking Cessation Program; Therapist Guide
[63]; see Figure 3). Topics discussed include identifying
Figure 3 Overview of session objectives.
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high-risk situations for smoking relapse, self-monitoring
of cigarette consumption, identifying maladaptive
thoughts and behaviors related to the maintenance of
smoking patterns, enlisting social support, and develop-
ing coping strategies. The first 5 weeks of the interven-
tion serve as planning and preparation weeks. The first
day of week 6 of the study is designated as ‘quit day’,
at which point participants are asked to make their
quit attempt (see Figure 2). At this time, all partici-
pants will be given the option to start NRT. Partici-
pants are carefully educated about the proper use of
the patch prior to quit day and are instructed to apply
one patch daily. Based on the number of cigarettes
they are smoking prior to quit day, clinicians offer
patients a choice of 21-mg patches (indicated for those
smoking >10 cigarettes per day), 14-mg patches (indi-
cated for those smoking 10 or less cigarettes per day),
or a 7-mg patch (indicated for those smoking <10
cigarettes per day). They gradually taper to a lower
dose of the patch every 2 weeks. All participants are
asked to taper off the lowest dose of the patch by week
14, at which time the patch is no longer provided. At
each session while using the patch, participants are asked
about current side effects they may be experiencing.
Again, participants can also elect not to use the patch.
Exercise intervention (EX)
Intervention overview One week following the base-
line session, participants in the exercise condition ini-
tiate a 15-week program involving three 45-min
exercise sessions each week. During weeks 1 to 7, the
first weekly exercise session is completed following
the CBT session. During the first session, clinicians
provide participants with a rationale for exercise as a
treatment for smoking cessation. They are given a
model of the role of AS in the maintenance of smok-
ing, and told how interoceptive exposure (exposure to
aversive bodily sensations) plays a role in the treat-
ment of AS. Exercise is then introduced as a means
of systematic interoceptive exposure. Participants work
together with their therapist to develop an exercise
training progression schedule which allows participants
to gradually increase their intensity across weeks to
reach their prescribed dose by week 4 (see Figure 2).
By week 4, participant’s target exercise intensity dose
is 77% to 85% of their maximum heart rate (HR)
achieved during the pretreatment maximal exercise
test.
Exercise sessions Trained and CPR-certified staff super-
vises exercise sessions. During the session, participants
wear a HR monitor to confirm that they are training at
the targeted exercise intensity. Participants commence
the exercise session by performing an active warm-up of
5 min in duration at a progressively increasing speed
until the corresponding dose is achieved. Participants
then train at their target HR for 25 min. Five minutes
after the warm-up (10 min into the exercise session) and
every 5 min thereafter, participants are asked to rate
their anxiety and/or distress level using the Subjective
Units of Disturbance Scale (SUDS) [64]. Additionally,
they are also asked their rate of perceived exertion (RPE)
[65], speed, inclination of treadmill, and heart rate. At
minute 25, participants initiate a 5-min cool down
period during which their speed is gradually reduced. At
30 min, the exercise session concludes and participants
stretch with the clinician. Occasionally, participants are
reminded of and asked to explain the model and ration-
ale for exercise reducing AS (either before or after the
exercise session).
Wellness education intervention (CTRL)
Similar to the exercise intervention, the wellness educa-
tion intervention is a 15-week program involving three
45-min sessions each week. The wellness education
protocol was modeled after that used in previous studies
of exercise for smoking cessation [60,66]. Specifically,
during the first session, participants receive a thorough
description of the wellness program along with a rationale
for the intervention. Participants are given the rationale
that, because people who quit smoking often adopt
healthy lifestyle changes after smoking, we have opted to
include these changes from the onset of the quit attempt
to determine whether the addition of these lifestyle
changes during a quit attempt has an effect on smoking
cessation outcomes. They are also advised that focusing
on small wellness goals each week and gaining small suc-
cesses may carry over into their smoking cessation goals.
Wellness education sessions focus on discussions of a var-
iety of healthy lifestyle topics, such as healthy eating,
stress and time management, recommended health
screenings, and cancer and cardiovascular prevention.
The content in each session is delivered using a combin-
ation of lectures, videos, handouts, and discussions while
allowing participants to set their own realistic wellness
goals, which they can gradually incorporate into their
lives.
Assessment instruments
Table 1 provides an overview of the frequency and tim-
ing of administration for the primary assessments instru-
ments that are used for screening, to measure post-
cessation smoking outcomes and putative mediators,
and to measure treatment integrity and acceptance. A
description of each of these measures is provided next.
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Measures for screening
Smoking history Smoking history is assessed at Pre-
screen using indices agreed upon by a National Cancer
Institute consensus panel [67]. These indices include
measurements of brand and nicotine content of cigarette
type, rate of smoking, previous quit attempts and dur-
ation, household smokers, age of onset of smoking,
and more. This instrument has been successfully used
in our previous work [43].
Anxiety sensitivity The 16-item Anxiety Sensitivity
Index (ASI-16; [25]) is employed to assess sensitivity to
and discomfort with physical sensations. The ASI demon-
strates good retest reliability and internal consistency,
and excellent convergent validity with other established
measures [68,69]. This measure is administered at Pre-
screen as an eligibility assessment.
Suicidality The Columbia Suicide Severity Rating Scale
(C-SSRS; [70]) is administered at Screening Visit 1. The
C-SSRS is a standardized measure of current and past
self-injurious behavior, suicidal intent, and suicidal beha-
viors, and demonstrates good reliability and validity
[70,71].
Psychiatric diagnoses At Screening Visit 1, the Struc-
tured Clinical Interview for DSM-IV non-patient version
(SCID-NP) [72] is administered to determine diagnostic
exclusions and lifetime prevalence of Axis I diagnoses.
The SCID is administered by trained doctoral-level
interviewers who are supervised by the senior investiga-
tors (JAJS and MBP), as has been done successfully in
the past (for example, [43,54]).
Medical history The physician obtains medical history,
which includes, but is not limited to, medical diagnosis,
previous physical examination findings, history of symp-
toms, orthopedic problems, medication use, exercise his-
tory, and family history.
Physical exam The physician completes a physical
exam, which includes: height, body weight, apical pulse
rate and rhythm, resting blood pressure, auscultation of
the lungs, palpation of the cardiac apical impulse, point
of maximal impulse, auscultation of the heart, palpation
and auscultation of the carotid, abdominal, and femoral
arteries, evaluation of the abdomen, palpation and in-
spection of lower extremities, tests of neurologic func-
tion, and inspection of the skin.
Laboratory testing Laboratory testing is performed in-
cluding hematology (for example, hemoglobin; hematocrit,
red blood cell count (RBC); mean corpuscular hemoglobin
(MCH), mean corpuscular hemoglobin concentration
(MCHC); mean corpuscular volume (MCV), WBC
with differential; and platelet count), biochemistry (so-
dium; potassium; calcium; chloride; glucose; triglycer-
ides; cholesterol (total); protein (total); blood urea
nitrogen (BUN); albumin; creatinine; alkaline phosphat-
ase; bilirubin; aspartate aminotransferase (AST); alanine
aminotransferase (ALT); and gammaglutamyl transpep-
tidase (γGT)), and serum pregnancy test (for women).
Maximal exercise testing A maximal exercise test
adapted from the Cornell protocol [73] is performed
during screening (pretreatment) and at week 16 to
examine the participants’ fitness level and obtain an as-
sessment of maximum HR to formulate exercise dose.
Though there are many protocols available for exercise
testing, we chose the Cornell protocol because we feel it
is less of a burden on participants, thus giving us more
accurate results. The Cornell protocol is similar to the
Bruce protocol; however, the Cornell protocol is divided
into smaller and shorter stages and is generally more
applicable to patients with limited exercise tolerance
because of the smaller workload increments. Prior to
the test, a resting ECG is taken and resting HR and
blood pressure are measured. Participants then exercise
at a rate that gradually increases in speed and incline
in 2-min intervals for a maximum of 14 min. Partici-
pants are instructed that they may stop exercising at
any point, but are encouraged to continue until they
reach their maximal exercise dose. Maximal exercise is
defined as an inability to continue exercise despite vig-
orous encouragement. Heart rate is measured continu-
ously by ECG, and blood pressure is monitored every 2
to 3 min by recording brachial artery cuff pressure.
Measures of post-cessation smoking outcomes
Smoking status Self-reports of smoking status are col-
lected from participants weekly from quit day through
Week 10 post-quit day and at Weeks 16 and 24 post-
quit day. Participant reports of abstinence at all assess-
ments are verified by expired carbon monoxide, and
additionally with saliva cotinine at the 16- and 24-week
interviews (see Table 1). The main outcome analyses are
based upon 7-day point prevalence abstinence (that is,
reported abstinence of at least 7 days prior to each
scheduled follow-up). Self-report is always overridden by
objective verification in the conservative direction [74].
In addition to point-prevalence outcomes, we also use
the TLFB procedure for assessing the time to first smok-
ing lapse and the time to first relapse, defined as the sev-
enth day on which smoking occurs. The TLFB
procedure demonstrates good reliability and validity [75]
and we recently validated the TLFB for the assessment
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of adult cigarette use and to measure smoking among
high AS persons over time [76]. The TLFB is adminis-
tered at each assessment to assess cigarette use since the
previous assessment.
Biochemical verification Self-reported abstinence at
the 16- and 24-week follow-ups are verified by saliva
cotinine (cutoff value of 10 ng/mL) for stated abstinence
of 2 weeks or more (cotinine may be incompletely meta-
bolized before this time), and carbon monoxide analysis
of breath samples (8 ppm cut-off ) for stated abstinence
of 24 h to 2 weeks [62]. Saliva samples are frozen for
shipment to an outside laboratory, which determines
cotinine level by radioimmune assay. Expired air carbon
monoxide levels are assessed with a carbon monoxide
monitor [62]. Detected values above the stated cutoff
scores are considered indicative of smoking.
Measures of putative mediators
Minnesota withdrawal scale We monitor withdrawal
severity with the Minnesota Withdrawal Scale (MWS), a
10-item scale that is reliable and sensitive [77,78].
Anxiety sensitivity index-III The Anxiety Sensitivity
Index-III (ASI-III) is an 18-item measure in which
respondents indicate the degree to which they are con-
cerned about possible negative consequences of anxiety-
related symptoms [79]. These items were derived from
the Anxiety Sensitivity Index (ASI) [25] and the Anxiety
Sensitivity Index-Revised (ASI-R) [80]. ASI-III and its
subscales show improvements over previous measures of
the construct regarding reliability and factorial validity;
as well as convergent, discriminant, and criterion-related
validity [79].
Inventory of depression and anxiety symptoms The
Inventory of Depression and Anxiety Symptoms (IDAS)
is a 64-item measure designed to assess specific symp-
toms of major depression and anxiety disorders [81].
The scales are internally consistent, show excellent
convergent validity, and demonstrate good discriminant
validity [81].
Measures of treatment integrity and acceptance
Treatment credibility and expectancy The Treatment
Credibility/Expectancy Questionnaire (CEQ) is a com-
monly used six-item measure assessing treatment cred-
ibility and expectancy [82]. We administer the scale after
the first treatment sessions of the ST+CTRL and ST+EX
protocols to later examine whether treatment expect-
ancy or credibility varied between the intervention
conditions.
Therapist adherence All sessions for CBT and the
CTRL interventions are audio-taped and 10% will be
rated by independent raters (that is, raters not otherwise
associated with the treatment delivery) to assess therap-
ist adherence to and competence with the treatment
protocol. Rating checklists and scales were developed for
this use.
Patient adherence Patient adherence to the smoking
cessation intervention, exercise intervention, and wellness
program are assessed by taking attendance at each session
(that is, number of total sessions attended). Adherence to
the nicotine patch usage is assessed at Weeks 1 to 8 fol-
lowing the quit date. A significant difference in fitness
(functional capacity) as expressed in METs between ST
+EX and ST+CTRL conditions provides evidence of in-
tegrity of the exercise intervention. An assessment team
that is blind to study condition will conduct the exercise
testing.
Adverse events During the treatment period of the study,
the assessment of adverse events occurs at each weekly as-
sessment using standard reporting forms. Participants’
blood pressure (using a brachial artery cuff) and pulse are
measured at baseline and at each weekly assessment
Concurrent treatment Use of medications other than
nicotine patch, other aids to smoking cessation, and par-
ticipation in any concurrent psychotherapeutic treat-
ment are assessed at each major outcome assessment
(for example, baseline, quit date, weeks 2, 4, 8, 10, 16,
and 24 following quit date) point.
Analytic methods
Our analyses of the effects of treatment on point preva-
lence abstinence (PPA) will be conducted using General-
ized Linear Mixed Models (GLMM) because it includes
all subjects in the analysis, regardless of whether they
have missing data. This approach to analyzing PPA was
recommended by a working group formed by the Society
for Research on Nicotine and Tobacco [83].
The growth curve of abstinence rates over time will be
modeled as quadratic because previous research [60]
indicates that abstinence rapidly decreases shortly after
quit date, but the rate of decline in abstinence levels off
over time. We will focus on treatment differences in the
slope of change in PPA because slopes have lower vari-
ance and greater reliability than means at particular
assessments [84], thus yielding greater power and better
generalizability. Secondarily, we will test for differences
between treatment conditions at particular assessment
points by centering our time variable at that particular
assessment.
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Cox proportional hazards survival analysis will be
employed to examine the extent to which ST+EX
increases the latency to first smoking. We expect that
ST+EX will be associated with a lower risk of lapsing
compared to ST+CTRL. Also, we expect mean time to
smoking relapse (defined as the seventh occurrence of
smoking after quit date) to be longer for those assigned
to ST+EX than those assigned to ST+CTRL.
The paths in the mediation model shown in Figure 1
will be calculated using multilevel models (MLM) to as-
sess the ‘a’ paths and GLMM to assess the ‘b’ paths. Each
indirect, mediated pathway (for example, the effect of
treatment on abstinence that is mediated by AS, path
a3*b3) will be tested for significance using bias-corrected
bootstrapping [85]. We expect each mediated pathway
to be moderated by exercise condition. Thus, we will fol-
low the procedures suggested by Tein and colleagues
[86] to calculate the size of the mediated pathway for
each treatment condition separately.
Treatment dose Because some of our participants will
not attend all treatment sessions, we will include num-
ber of treatment sessions received as an additional pre-
dictor in our major analyses. If treatment dose has a
significant impact on outcomes, we will use the proce-
dures suggested by Aiken and West [87] to determine
the level of dosage necessary for a significant treatment
effect on abstinence.
Missing data Following the suggestions of Hall and col-
leagues [83], we will rerun our primary analyses including
dummy codes for various missing data patterns (for ex-
ample, no missing data, sporadic missing, or all missing
after a certain time point) to determine if missingness
impacts our findings and if the differences between ST
+EX and ST+CTRL depend on the missing data pattern
(that is, pattern mixture modeling [88]).
Power analyses We performed Monte Carlo simula-
tions to estimate the sample size necessary to detect
hypothesized effect sizes in our analyses. Since the medi-
ation analysis has the lowest power, sample size esti-
mates were based on that analysis. We assumed that we
would obtain an average of 57% (4 out of 7) of the
assessments from the participants. Our Monte Carlo
analysis performed 500 simulations, with each simula-
tion computing a bias-corrected bootstrapping analysis
of the mediated effects using 1,200 resamples. Results
indicate that it would take a sample size of 150 to have a
power of 0.80 to detect significant mediated effect if the
‘a’ path has a large effect size and the ‘b’ path has a
medium effect size (see Figure 1). Thus, our target sam-
ple size was set at 150.
Next, we determined the power for our primary hy-
pothesis that PPA at the 6-month follow-up would be
higher in ST+EX than in ST+CTRL. Given the sample
size of 150 determined by our mediation power analysis,
we calculated the smallest PPA that we could detect with
power >0.80. Assuming that the PPA in ST+CTRL will
be 20% [60], our Monte Carlo simulations indicate that
we will be able to detect a significant difference between
ST+EX and ST+CTRL with power >0.80 if the PPA rate
in ST+EX is 35% or greater.
Rationale for key study protocol choices
Sample
A key decision was the selection of participants high in
AS as opposed to some other anxiety or mood-related risk
factor, because of the specific prediction offered by AS
across multiple studies (see introduction). High AS is
operationalized by an ASI-16 score of ≥20. Also, we chose
to study adult daily smokers who are currently motivated
to quit because our intervention will not involve any mod-
ules (for example, motivational interviewing) designed to
increase motivation for cessation. Smokers using other
types of nicotine products (for example, smokeless
tobacco, cigars) will not be included in the sample, as the
study was designed specifically for reducing cigarette
smoking. Assessments of cigarette smoking could be con-
founded by inclusion of other types of nicotine products.
Inclusion of nicotine patch in standard treatment
Because recent clinical guidelines recommend that all
smokers attempting to quit smoking receive pharmaco-
therapy [89,90], we believe it is important to make
pharmacotherapy available as part of our standard smok-
ing cessation treatment. We selected the transdermal
nicotine patch (TNP) because of the extensive empirical
literature supporting its effectiveness and safety, its ease
of use, and its relatively benign side effect profile, which
have led to its approval as an over-the-counter medica-
tion. We chose to provide the patch for 8 weeks because
use of TNP for longer than 8 weeks does not appear to
improve treatment efficacy [91]. Overall, using TNP with
standard smoking counseling allows us to examine if the
ST+EX is more efficacious than existing (standard) treat-
ment. Because TNP is optional, its use will be tracked
for each study participant.
Dose, duration, and format of the exercise intervention
We elected to use the public health recommended dose
of vigorous-intensity exercise (that is, 75 min of aerobic
exercise at >76% of maximum heart rate per week [2];
because: (1) research suggests that it can yield large
reductions in AS [54]; and (2) a comparable dose was
employed in the [60] study that demonstrated the effi-
cacy of exercise as an aid for smoking cessation. In order
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to ensure that the exercise intervention is of sufficient
duration [57], we decided to match the length of the
exercise intervention (that is, 15 weeks) to that of
established psychotherapies that show clear efficacy for
reducing AS, depressed mood, and anxiety among
individuals with elevated levels of AS (for example,
cognitive-behavioral treatment of panic disorder; for
example, [92-94]). Consistent with the American College
of Sports Medicine (ACSM) exercise prescription guide-
lines [95], participants are encouraged to progress to the
study dose during the first 3 weeks (by varying intensity
and duration of exercise) of the smoking cessation pro-
gram. From week 4 (that is, 2 weeks prior to the quit
date; see Table 1) to week 15, participants are expected to
exercise at the study dose. Finally, participants are
required to complete their exercise sessions at the study
site’s exercise facility under the supervision of a trained
staff member. Our decision to utilize a supervised instead
of a combination supervised/home-based format, which
may be more attractive from a cost-efficacy perspective,
is guided by the specific aims of our study. Specifically, in
order to examine the efficacy and mechanisms of exer-
cise for smoking cessation, it is essential to achieve the
highest intervention adherence rates possible, which is
more easily accomplished using a supervised instead of a
combination supervised/home-based format (for example,
[60,66]).
Inclusion of a control condition
In order to isolate the effects of the exercise interven-
tion, while at the same time reducing the risk of differ-
ential attrition, we needed to equate the two conditions
for common factors (for example, expectancy effects, de-
mand characteristics, social contact, expert contact). We
are accomplishing this by requiring participants who are
not assigned to receive the exercise intervention to at-
tend a 15-week Wellness Program. The Wellness Pro-
gram was developed and previously implemented
effectively by our team (for example, [60,66]). Matching
the exercise intervention for contact time, participants
attend three 45-min sessions each week. Each session
(for example, lectures, handouts, films, and discussions)
focuses on lifestyle issues, such as healthy eating and
prevention of cancer and cardiovascular disease.
Using a 6-month over a 12-month follow-up
We had several reasons for choosing a 6-month post-
quit follow-up over a 12-month follow-up. First, a
6-month follow-up seems reasonable given the well-
accepted observation that most smoking relapses occur
in the first 3 months post-cessation [89,90]. Second, we
want to examine point prevalence abstinence at a num-
ber of key time points of interest: 2, 4, 8, 10, 16, and
24 weeks following quit date (see Figure 2 and Table 1).
The first two time points reflect our particular interest
in immediate vulnerability to relapse as a result of ele-
vated anxiety symptoms. Week 2 also corresponds to the
end of the CBT intervention. Week 8 corresponds to the
end of nicotine patch usage, Week 10 corresponds to
the end of the EX/CTRL interventions, and Weeks 16
and 24 allow for longer-term follow-up. However, it
should be noted that we also employ the smoking
TLFB interview, which provides information on daily
smoking rates over the 6-month follow-up. We previ-
ously demonstrated the reliability and validity of the
TLFB method for use in assessing adult smoking out-
comes [63].
Discussion
The primary objective of the STEP study is to contribute
to the growing body of literature calling for the develop-
ment of specialized smoking cessation interventions for
anxiety vulnerable individuals. If effective, the use of
exercise as a component of treatment for smoking ces-
sation would have a significant public health impact.
In addition to improving smoking cessation treatment
outcome, exercise is expected to offer benefits to over-
all health, which may be particularly important for
smokers. Further, the proposed study (that is, design,
assessment schedule, and analyses) offers the potential
to improve the understanding of the mechanisms that
underlie these effects. The specific design considerations
of the exercise intervention provide a dose and intensity
that is thought to enact beneficial biological and psycho-
logical changes while also allowing for participant satis-
faction and flexibility. The utilization of a wellness
education group provides an adequate, time-matched
control necessary in order to examine the specific effects
of exercise.
The anticipated benefits of the study are twofold: (1)
the results will yield knowledge about the combined
effects of exercise with standard smoking cessation treat-
ment; and (2) the results will advance understanding of
the factors related to anxiety and relapse to smoking
after attempts at smoking cessation. The results of the
study may also inform strategies to match treatments to
specific characteristics of smokers. Lastly, data yielded
by this study is expected to guide future studies that aim
to determine the optimal dose and intensity for exercise-
based smoking cessation interventions as well strategies
to enhance motivation to exercise and motivation to quit
smoking.
Trial status
The trial is currently in the recruitment phase.
Abbreviations
ACSM: American College of Sports Medicine; AS: Anxiety sensitivity;
CBT: Cognitive behavioral therapy; NRT: Nicotine replacement therapy;
Smits et al. Trials 2012, 13:207 Page 12 of 15
http://www.trialsjournal.com/content/13/1/207
PPA: Point prevalence abstinence; ST: Standard treatment; ST+CTRL: Standard
treatment plus control condition; ST+EX: Standard treatment plus exercise
condition; STEP: Smoking Termination Enhancement Project; TLFB: Timeline
follow back.
Competing interests
Drs Smits and Otto receive royalties from Oxford University Press for books
on exercise for mood and anxiety disorders. All other authors declare that
they have no competing interests.
Authors' contributions
JAJS and MJZ conceived the study and participated in its design and
coordination. DR, BHM, TSC, GMF, MBP, and MWO contributed to the design
of the study and provided consultation and supervision. MLD, LBD, and NFB
participated in the coordination of the study. All authors contributed to the
drafting of the manuscript and have read and approved the final manuscript.
Acknowledgements
We are grateful to the numerous colleagues who provided clinical and
research support in treating and following the patients included in this trial.
We would also like to thank Stephanie Burns and Audra Ames for their
administrative support.
Author details
1Department of Psychology, Southern Methodist University, Dedman College,
P.O. Box 750442, Dallas, TX 75275, USA. 2Department of Psychology,
University of Houston, Houston, TX, USA. 3Department of Family & Preventive
Medicine, University of California, San Diego, CA, USA. 4Pennington
Biomedical Research Center, Louisiana State University, Baton Rouge, LA,
USA. 5Department of Psychology, Howard University, Washington, DC, USA.
6Department of Psychology, Boston University, Boston, MA, USA.
Received: 28 September 2012 Accepted: 30 October 2012
Published: 13 November 2012
References
1. U.S. Department of Health and Human Services: Health, United States, 2004
with Chartbook on Trends in the Health of Americans. Hyattsville, MD: U.S.
Government Printing Office; 2004.
2. U.S. Department of Health and Human Services: Treating Tobacco Use and
Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S.
Public Health Service; 2008.
3. Samet JM: Health benefits of smoking cessation. Clin Chest Med 1991,
12:669–679.
4. Centers for Disease Control and Prevention: Tobacco use among adults -
United States, 2005. MMWR Morb Mortal Wkly Rep 2006, 55:1145–1148.
5. Centers for Disease Control and Prevention: Cigarette smoking among
adults: United States, 2000. MMWR Morb Mortal Wkly Rep 2002,
51:642–645.
6. Garvey AJ, Heinold JW, Rosner B: Self-help approaches to smoking
cessation: a report from the normative aging study. Addict Behav 1989,
14:23–33.
7. Brown RA, Emmons KM: Behavioral treatment of cigarette dependence. In
The Clinical Management of Nicotine Dependence. Edited by Cocores JA. New
York, NY: Springer; 1991:97–118.
8. Schwartz DA: Review and Evaluation of Smoking Cessation Methods: The
United States and Canada. Bethesda, MD: National Cancer Institute; 1987.
9. Irvin JE, Brandon TH: The increasing recalcitrance of smokers in clinical
trials. Nicotine Tob Res 2000, 2:79–84.
10. Piasecki TM, Baker TB: Any further progress in smoking cessation
treatment? Nicotine Tob Res 2001, 3:311–323.
11. Shiffman S: Smoking cessation treatment: any progress? J Consult Clin
Psychol 1993, 61:718–722.
12. Coambs RB, Kozlowski L, Ferrence RG: The future of tobacco use and
smoking research. In Smoking and Human Behavior. Edited by Nay T, Gale
A. New York, NY: Wiley; 1989:337–348.
13. Hughes JR: Pharmacotherapy for smoking cessation: unvalidated
assumptions, anomalies, and suggestions for future research. J Consult
Clin Psychol 1993, 61:751–760.
14. Hughes JR, Brandon TH: A softer view of hardening. Nicotine Tob Res 2003,
5:961–962.
15. Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE,
Audrain-McGovern J, Breslau N, Brown RA, George TP, Williams J, Calhoun
PS, Riley WT: Tobacco use and cessation in psychiatric disorders: National
Institute of Mental Health report. Nicotine Tob Res 2008, 10:1691–1715.
16. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH:
Smoking and mental illness: a population-based prevalence study. JAMA
2000, 284:2606–2610.
17. Acierno R, Kilpatrick DG, Resnick H, Saunders B, De Arellano M, Best C:
Assault, PTSD, family substance use, and depression as risk factors for
cigarette use in youth: findings from the National Survey of Adolescents.
J Trauma Stress 2000, 13:381–396.
18. Acierno RA, Kilpatrick DG, Resnick HS, Saunders BE, Best CL: Violent assault,
posttraumatic stress disorder, and depression. Risk factors for cigarette
use among adult women. Behav Modif 1996, 20:363–384.
19. Buckley TC, Mozley SL, Bedard MA, Dewulf AC, Greif J: Preventive health
behaviors, health-risk behaviors, physical morbidity, and health-related
role functioning impairment in veterans with post-traumatic stress
disorder. Mil Med 2004, 169:536–540.
20. Dobie DJ, Kivlahan DR, Maynard C, Bush KR, Davis TM, Bradley KA:
Posttraumatic stress disorder in female veterans: association with
self-reported health problems and functional impairment. Arch Intern
Med 2004, 164:394–400.
21. Zvolensky MJ, Schmidt NB, Stewart SH: Panic disorder and smoking. Clin
Psychol Sci Pract 2003, 10:29–51.
22. Zvolensky M, Bernstein A, Yartz AR: Cognitive-behavioral treatment of
co-morbid panic psychopathology and tobacco use and dependence. In
Anxiety Substance Use Disorders. 2008:177–200.
23. Hapke U, Schumann A, Rumpf HJ, John U, Konerding U, Meyer C:
Association of smoking and nicotine dependence with trauma and
posttraumatic stress disorder in a general population sample. J Nerv
Ment Dis 2005, 193:843–846.
24. Piper ME, Smith SS, Schlam TR, Fleming MF, Bittrich AA, Brown JL, Leitzke
CJ, Zehner ME, Fiore MC, Baker TB: Psychiatric disorders in smokers
seeking treatment for tobacco dependence: relations with tobacco
dependence and cessation. J Consult Clin Psychol 2010, 78:13–23.
25. Reiss S, Peterson RA, Gursky DM, McNally RJ: Anxiety sensitivity, anxiety
frequency and the prediction of fearfulness. Behav Res Ther 1986, 24:1–8.
26. Hayward C, Wilson KA: Anxiety sensitivity: a missing piece to the
agoraphobia-without-panic puzzle. Behav Modif 2007, 31:162–173.
27. Li W, Zinbarg RE: Anxiety sensitivity and panic attacks: a 1-year
longitudinal study. Behav Modif 2007, 31:145–161.
28. Marshall GN, Miles JN, Stewart SH: Anxiety sensitivity and PTSD symptom
severity are reciprocally related: evidence from a longitudinal study of
physical trauma survivors. J Abnorm Psychol 2010, 119:143–150.
29. Schmidt NB, Keough ME, Mitchell MA, Reynolds EK, Macpherson L,
Zvolensky MJ, Lejuez CW: Anxiety sensitivity: prospective prediction
of anxiety among early adolescents. J Anxiety Disord 2010, 24:503–508.
30. Schmidt NB, Lerew DR, Jackson RJ: The role of anxiety sensitivity in the
pathogenesis of panic: prospective evaluation of spontaneous panic
attacks during acute stress. J Abnorm Psychol 1997, 106:355–364.
31. Schmidt NB, Lerew DR, Jackson RJ: Prospective evaluation of anxiety
sensitivity in the pathogenesis of panic: replication and extension.
J Abnorm Psychol 1999, 108:532–537.
32. Schmidt NB, Zvolensky MJ, Maner JK: Anxiety sensitivity: prospective
prediction of panic attacks and Axis I pathology. J Psychiatr Res 2006,
40:691–699.
33. Maller R, Reiss S: Anxiety sensitivity in 1984 and panic attacks in 1987.
J Anxiety Disord 1992, 6:241–247.
34. Battista SR, Stewart SH, Fulton HG, Steeves D, Darredeau C, Gavric D: A
further investigation of the relations of anxiety sensitivity to smoking
motives. Addict Behav 2008, 33:1402–1408.
35. Comeau N, Stewart SH, Loba P: The relations of trait anxiety, anxiety
sensitivity, and sensation seeking to adolescents’ motivations for
alcohol, cigarette, and marijuana use. Addict Behav 2001,
26:803–825.
36. Leyro TM, Zvolensky MJ, Vujanovic AA, Bernstein A: Anxiety sensitivity and
smoking motives and outcome expectancies among adult daily smokers:
replication and extension. Nicotine Tob Res 2008, 10:985–994.
37. Novak A, Burgess ES, Clark M, Zvolensky MJ, Brown RA: Anxiety sensitivity,
self-reported motives for alcohol and nicotine use, and level of
consumption. J Anxiety Disord 2003, 17:165–180.
Smits et al. Trials 2012, 13:207 Page 13 of 15
http://www.trialsjournal.com/content/13/1/207
38. Stewart SH, Karp J, Pihl RO, Peterson RA: Anxiety sensitivity and
self-reported reasons for drug use. J Subst Abuse 1997, 9:223–240.
39. Zvolensky MJ, Bonn-Miller MO, Bernstein A, McLeish AC, Feldner MT,
Leen-Feldner EW: Anxiety sensitivity interacts with marijuana use in the
prediction of anxiety symptoms and panic-related catastrophic thinking
among daily tobacco users. Behav Res Ther 2006, 44:907–924.
40. Brown RA, Kahler CW, Zvolensky MJ, Lejuez CW, Ramsey SE: Anxiety
sensitivity: relationship to negative affect smoking and smoking
cessation in smokers with past major depressive disorder. Addict Behav
2001, 26:887–899.
41. Gregor KL, Zvolensky MJ, McLeish AC, Bernstein A, Morissette S: Anxiety
sensitivity and perceived control over anxiety-related events:
associations with smoking outcome expectancies and perceived
cessation barriers among daily smokers. Nicotine Tob Res 2008,
10:627–635.
42. Zvolensky MJ, Vujanovic AA, Miller MO, Bernstein A, Yartz AR, Gregor KL,
McLeish AC, Marshall EC, Gibson LE: Incremental validity of anxiety
sensitivity in terms of motivation to quit, reasons for quitting, and
barriers to quitting among community-recruited daily smokers. Nicotine
Tob Res 2007, 9:965–975.
43. Zvolensky MJ, Baker KM, Leen-Feldner E, Bonn-Miller MO, Feldner MT,
Brown RA: Anxiety sensitivity: association with intensity of
retrospectively-rated smoking-related withdrawal symptoms and
motivation to quit. Cogn Behav Ther 2004, 33:114–125.
44. Johnson KA, Stewart S, Rosenfield D, Steeves D, Zvolensky MJ: Prospective
evaluation of the effects of anxiety sensitivity and state anxiety in
predicting acute nicotine withdrawal symptoms during smoking
cessation. Psychol Addict Behav 2012, 26:289–297.
45. Mullane JC, Stewart SH, Rhyno E, Steeves D, Darredeau C, Gavric D: Anxiety,
sensitivity and difficulties with smoking cessation. In Advances in
Psychological Research, Volume 3. Edited by Columbus FH. New York, NY:
Nova; 2008:141–155.
46. Vujanovic AA, Zvolenksy MJ: Anxiety sensitivity, acute nicotine withdrawal
symptoms, and anxious and fearful responding to bodily sensations:
A laboratory test. Exp Clin Psychopharmacol 2009, 17:3–181.
47. Wong M, Krajisnik A, Truong L, Lisha N, Trujillow M, Greenberg JB, Kahler
CW, Zvolensky MJ, Leventhal AM: Anxiety sensitivity as a predictor of
acute subjective effects of smoking. Nicotine Tob Res. in press.
48. Zvolensky MJ, Bernstein A: Cigarette smoking and panic psychopathology.
Curr Dir Psychol Sci 2005, 14:301–305.
49. Zvolensky MJ, Bernstein A, Cardenas SJ, Colotla VA, Marshall EC, Feldner MT:
Anxiety sensitivity and early relapse to smoking: a test among Mexican
daily, low-level smokers. Nicotine Tob Res 2007, 9:483–491.
50. Zvolensky MJ, Stewart SH, Vujanovic AA, Gavric D, Steeves D: Anxiety
sensitivity and anxiety and depressive symptoms in the prediction of
early smoking lapse and relapse during smoking cessation treatment.
Nicotine Tob Res 2009, 11:323–331.
51. Zvolensky MJ, Bonn-Miller MO, Feldner MT, Leen-Feldner E, McLeish AC,
Gregor K: Anxiety sensitivity: Concurrent associations with negative
affect smoking motives and abstinence self-confidence among young
adult smokers. Addict Behav 2006, 31:429–439.
52. Zvolensky MJ, Kotov R, Antipova AV, Schmidt NB: Cross cultural evaluation
of smokers risk for panic and anxiety pathology: a test in a Russian
epidemiological sample. Behav Res Ther 2003, 41:1199–1215.
53. Broman-Fulks JJ, Berman ME, Rabian BA, Webster MJ: Effects of aerobic
exercise on anxiety sensitivity. Behav Res Ther 2004, 42:125–136.
54. Smits JA, Berry AC, Rosenfield D, Powers MB, Behar E, Otto MW:
Reducing anxiety sensitivity with exercise. Depress Anxiety 2008,
25:689–699.
55. Smits JAJ, Powers MB, Berry AC, Otto MW: Translating empirically
supported strategies into accessible interventions. The potential utility of
exercise for the treatment of panic disorder. Cogn Behv Pract 2007,
14:344–374.
56. Bock BC, Marcus BH, King TK, Borrelli B, Roberts MR: Exercise effects on
withdrawal and mood among women attempting smoking cessation.
Addict Behav 1999, 24:399–410.
57. Ussher MH, Taylor A, Faulkner G: Exercise interventions for smoking
cessation. Cochrane Database Syst Rev 2008, (4). CD002295.
58. Stathopoulou G, Powers MB, Berry AC, Smits JAJ, Otto MW: Exercise
interventions for mental health: a quantitative and qualitative review.
Clin Psychol Sci Pract 2006, 13:179–193.
59. DeBoer LB, Powers MB, Utschig AC, Otto MW, Smits JA: Exploring exercise
as an avenue for the treatment of anxiety disorders. Expert Rev Neurother
2012, 12:1011–1022.
60. Marcus BH, Albrecht AE, King TK, Parisi AF, Pinto BM, Roberts M, Niaura RS,
Abrams DB: The efficacy of exercise as an aid for smoking cessation in
women: a randomized controlled trial. Arch Intern Med 1999,
159:1229–1234.
61. Schmidt NB, Joiner TE: Structure of the anxiety sensitivity index
psychometrics and factor structure in a community sample. J Anxiety
Disord 2002, 16:33–49.
62. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y: Comparison
of tests used to distinguish smokers from nonsmokers. Am J Public Health
1987, 77:1435–1438.
63. Zvolensky M, Yartz A, Gregor K, Gonzalez A, Bernstein A: Interoceptive
exposure-based cessation intervention for smokers high in anxiety
sensitivity: A case series. J Cogn Psychother 2008, 22:346–365.
64. Wolpe J: Psychotherapy by Recipricol Inhibition. Stanford, CA: Stanford
University Press; 1958.
65. Borg G, Ljunggren G, Ceci R: The increase of perceived exertion, aches
and pain in the legs, heart rate and blood lactate during exercise on a
bicycle ergometer. Eur J Appl Physiol Occup Physiol 1985, 54:343–349.
66. Marcus BH, Lewis BA, Hogan J, King TK, Albrecht AE, Bock B, Parisi AF,
Niaura R, Abrams DB: The efficacy of moderate-intensity exercise as an
aid for smoking cessation in women: a randomized controlled trial.
Nicotine Tob Res 2005, 7:871–880.
67. Shumaker SA, Grunberg NE: Proceedings of the national working
conference on smoking relapse. Health Psychol 1986, 5:1–17.
68. Peterson CA: A psychotic gynemimetic: I just had a pregnant thought.
J Pers Assess 1992, 58:464–479.
69. Zinbarg RE, Mohlman J, Hong NN: Dimensions of anxiety sensitivity.
In Anxiety Sensitivity: Theory, Research and Treatment of the Fear of Anxiety.
Edited by Taylor S. Hillsdale, NJ: Lawrence Earlbaum Associates;
1999:83–114.
70. Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia
classification algorithm of suicide assessment (C-CASA): classification
of suicidal events in the FDA’s pediatric suicidal risk analysis of
antidepressants. Am J Psychiatry 2007, 164:1035–1043.
71. Hammad TA, Laughren TP, Racoosin JA: Suicide rates in short-term
randomized controlled trials of newer antidepressants. J Clin
Psychopharmacol 2006, 26:203–207.
72. First MB, Pincus HA, Levine JB, Williams JB, Ustun B, Peele R: Clinical utility
as a criterion for revising psychiatric diagnoses. Am J Psychiatry 2004,
161:946–954.
73. Okin PM, Ameisen O, Kligfield P: A modified treadmill exercise protocol
for computer-assisted analysis of the ST segment/heart rate slope:
methods and reproducibility. J Electrocardiol 1986, 19:311–318.
74. Proceedings of the national working conference on smoking relapse.
July 24–26, Bethesda, Maryland. Health Psychol 1985, 1–99.
75. Sobell M, Sobell L: Problem Drinkers: Guided Self-Change Treatment. New
York, NY: Guilford Press; 1996.
76. McLeish AC, Zvolensky MJ, Bucossi MM: Interaction between smoking rate
and anxiety sensitivity: relation to anticipatory anxiety and panic-
relevant avoidance among daily smokers. J Anxiety Disord 2007,
21:849–859.
77. Hughes JR, Hatsukami D: Signs and symptoms of tobacco withdrawal.
Arch Gen Psychiatry 1986, 43:289–294.
78. Piasecki TM, Niaura R, Shadel WG, Abrams D, Goldstein M, Fiore MC, Baker
TB: Smoking withdrawal dynamics in unaided quitters. J Abnorm Psychol
2000, 109:74–86.
79. Taylor S, Zvolensky MJ, Cox BJ, Deacon B, Heimberg RG, Ledley DR,
Abramowitz JS, Holaway RM, Sandin B, Stewart SH, Coles M, Eng W, Daly ES,
Arrindell WA, Bouvard M, Cardenas SJ: Robust dimensions of anxiety
sensitivity: development and initial validation of the Anxiety Sensitivity
Index-3. Psychol Assess 2007, 19:176–188.
80. Taylor S, Cox BJ: An expanded anxiety sensitivity index: evidence for a
hierarchic structure in a clinical sample. J Anxiety Disord 1998, 12:463–483.
81. Watson D, O'Hara MW, Simms LJ, Kotov R, Chmielewski M, McDade-Montez
EA, Gamez W, Stuart S: Development and validation of the inventory of
depression and anxiety symptoms (IDAS). Psychol Assess 2007, 19:253–268.
82. Devilly GJ, Borkovec TD: Psychometric properties of the credibility/
expectancy questionnaire. J Behav Ther Exp Psychiatry 2000, 31:73–86.
Smits et al. Trials 2012, 13:207 Page 14 of 15
http://www.trialsjournal.com/content/13/1/207
83. Hall SM, Delucchi KL, Velicer WF, Kahler CW, Ranger-Moore J, Hedeker D:
Statistical analysis of randomized trials in tobacco treatment:
longitudinal designs with dichotomous outcome. Nicotine Tob Res 2001,
3:193–202.
84. Singer JD, Willet JD: Applied Longitudinal Data Analysis: Modeling Change
and Event Occurrence. New York, NY: Oxford University Press; 2003.
85. Mackinnon DP, Lockwood CM, Williams J: Confidence limits for the
indirect effect: distribution of the product and resampling methods.
Multivariate Behav Res 2004, 39:99.
86. Tein JY, Sandler IN, MacKinnon DP, Wolchik SA: How did it work? Who did
it work for? Mediation in the context of a moderated prevention effect
for children of divorce. J Consult Clin Psychol 2004, 72:617–624.
87. Aiken B, West SG: Multiple Regression: Testing and Interpreting Interactions.
Thousand Oaks, CA: Sage; 1991.
88. Enders CK: Missing not at random models for latent growth curve
analyses. Psychol Methods 2011, 16:1–16.
89. Fiore MC: US public health service clinical practice guideline: treating
tobacco use and dependence. Respir Care 2000, 45:1200–1262.
90. Fiore MC, Jaen CR: A clinical blueprint to accelerate the elimination of
tobacco use. JAMA 2008, 299:2083–2085.
91. Fiore MC, Smith SS, Jorenby DE, Baker TB: The effectiveness of the nicotine
patch for smoking cessation. A meta-analysis. JAMA 1994, 271:1940–1947.
92. Barlow DH, Gorman JM, Shear MK, Woods SW: Cognitive-behavioral
therapy, imipramine, or their combination for panic disorder: a
randomized controlled trial. JAMA 2000, 283:2529–2536.
93. Schmidt NB, Woolaway-Bickel K: The effects of treatment compliance on
outcome in cognitive-behavioral therapy for panic disorder: quality
versus quantity. J Consult Clin Psychol 2000, 68:13–18.
94. Smits JA, Powers MB, Cho Y, Telch MJ: Mechanism of change in
cognitive-behavioral treatment of panic disorder: evidence for the fear
of fear mediational hypothesis. J Consult Clin Psychol 2004, 72:646–652.
95. Pate RR, Pratt M, Blair SN: Physical activity and public health: a
recommendation from the Centers for Disease Control and Prevention
and the American College of Sports Medicine. JAMA 1995, 273:402–407.
doi:10.1186/1745-6215-13-207
Cite this article as: Smits et al.: The efficacy of vigorous-intensity
exercise as an aid to smoking cessation in adults with elevated anxiety
sensitivity: study protocol for a randomized controlled trial. Trials 2012
13:207.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Smits et al. Trials 2012, 13:207 Page 15 of 15
http://www.trialsjournal.com/content/13/1/207
